1. Vannucchi A. M., T. Barbui, F. Cervantes, C. Harrison, J.-J. Kiladjian, N. Kr ger, J. Thiele, Buske C. Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms: ESMO Clinical Practice Guidelines. Ann Oncol. 2015; 26 (5): 85 - 99.

2. A. Tefferi, T. Barbui. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification, and management. American Journal of Hematology. 2019; 94 (1) 133 - 143 https://doi.org/10.1002/ajh.25303.

3. Arellano-Rodrigo E, Alvarez-Larrnan A, Reverter JC, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2V617F allele burden. Am J Hematol. 2009; 84(2): 102 - 108.

4. Меликян А.Л., Ковригина А.М., Суборцева И.Н. и др. Национальные клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2018 г.) Гематология и трансфузиология. 2018; 63(3): 275 - 315. doi: 10.25837/HAT.2019.51.88.001.

5. Меликян А.Л., Ковригина А.М., Суборцева И.Н., и др. Национальные клинические рекомендации по диагностике и лечению Ph-негативных миелопролиферативных заболеваний (истинной полицитемии, эссенциальной тромбоцитемии, первичного миелофиброза) (редакция 2020 г.). Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2021; 14(2): 262 - 298. DOI: 10.21320/2500-2139-2021-14-2-262-298.

6. World Health Organization Classification of Haematolymphoid Tumours. 5th ed. Edited by WHO Classification of Tumors Editorial Board. IARCPress 2024, ISBN 9789283245209. Part A. pp 40 - 52.

7. Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, Jones C, Zehnder JL, Lilleberg SL, Weissman IL. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A. 2006 Apr 18; 103(16): 6224-9. doi: 10.1073/pnas.0601462103.

8. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005 Mar 19 - 25; 365(9464): 1054-61. doi: 10.1016/S0140-6736(05) 71142-9.

9. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28; 352(17): 1779-90. doi: 10.1056/NEJMoa051113.

10. Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, Ferrari M, Gisslinger H, Kralovics R, Cremonesi L, Skoda R, Cazzola M. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008 Feb 1; 111(3): 1686-9. doi: 10.1182/blood-2007-07-101576.

11. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006 Nov 15; 108(10): 3472-6. doi: 10.1182/blood-2006-04-018879.

12. Klampfl T, Gisslinger H, Harutyunyan ASet al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013 Dec 19; 369(25): 2379-90. doi: 10.1056/NEJMoa1311347.

13. Nangalia J, Massie CE, Baxter EJ, et.al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013 Dec 19; 369(25): 2391 - 2405. doi: 10.1056/NEJMoa1312542.

14. Pietra D, Rumi E, Ferretti VV, et.al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016 Feb; 30(2): 431-8. doi: 10.1038/leu.2015.277.

15. Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2014 Dec 5; 2014(1): 287-96. doi: 10.1182/asheducation-2014.1.287.

16. Milosevic Feenstra JD, Nivarthi H, et.al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016 Jan 21; 127(3): 325-32. doi: 10.1182/blood-2015-07-661835.

17. Rumi E, Pietra D, Pascutto C, et.al. Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014 Aug 14; 124(7): 1062-9. doi: 10.1182/blood-2014-05-578435.

18. Guglielmelli P, Pancrazzi A, Bergamaschi G, et.al. GIMEMA--Italian Registry of Myelofibrosis; MPD Research Consortium. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007 May; 137(3): 244-7. doi: 10.1111/j.1365-2141.2007.06565.x.

19. Lundberg P, Karow A, Nienhold R, et.al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014 Apr 3; 123(14): 2220-8. doi: 10.1182/blood-2013-11-537167.

20. Busque L, Porwit A, Day R, Olney HJ, Leber B, thier V, Sirhan S, Foltz L, Prchal J, Kamel-Reid S, Karsan A, Gupta V. Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian MPN Group. Am J Clin Pathol. 2016; 146(4): 408-22. doi: 10.1093/ajcp/aqw131.

21. Guglielmelli P, Lasho TL, Rotunno G, et.al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014 Sep; 28(9): 1804-10. doi: 10.1038/leu.2014.76.

22. Rotunno G, Pacilli A, Artusi V, et.al. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. Am J Hematol. 2016 Jul; 91(7): 681-6. doi: 10.1002/ajh.24377.

23. Tondeur S, Paul F, Riou J, et.al. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study. Leukemia. 2021 Mar; 35(3): 871 - 875. doi: 10.1038/s41375-020-0991-x.

24. Rotunno G, Mannarelli C, Guglielmelli P, et.al. Gruppo Italiano Malattie Mieloproliferative Investigators. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014 Mar 6; 123(10): 1552-5. doi: 10.1182/blood-2013-11-538983.

25. Alvarez-Larran A, Senin A, Fernandez-Rodriguez C, et.al. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2017 Sep; 178(5): 764 - 771. doi: 10.1111/bjh.14762.

26. Tefferi A, Lasho TL, Guglielmelli P, et.al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016 Nov 22; 1(1): 21 - 30. doi: 10.1182/bloodadvances.2016000216.

27. Senin A, Fernandez-Rodriguez C, Bellosillo B, et.al. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. Ann Hematol. 2018 Mar; 97(3): 443 - 451. doi: 10.1007/s00277-017-3193-5.

28. Moulard O., Mehta J., Fryzek J., et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014; 92(4): 289-97. https://doi.org/10.1111/ejh.12256.

29. Titmarsh G.J., Duncombe A.S., Mcmullin M.F., et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014; 89(6): 581-7. https://doi.org/10.1002/ajh.23690.

30. Pardanani A, Harrison C, Cortes JE, et al: Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol 1: 643-51, 2015.

31. Gangat N, Ilyas R, McCullough K, Begna KH, Al-Kali A, Patnaik MM, Litzow MR, Hogan WJ, Mangaonkar A, Alkhateeb H, Shah MV, Elliott MA, Foran JM, Badar T, Palmer JM, Hanson CA, Pardanani A, Tefferi A. Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm. Haematologica. 2023 May 1; 108(5): 1423 - 1428. doi: 10.3324/haematol.2022.282019. PMID: 36519330; PMCID: PMC10153526.

32. S. Thepot 1, R. Itzykson, V. Seegers, E. Raffoux, B. Quesnel, Y. Chait, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010 Nov 11; 116(19): 3735-42. doi: 10.1182/blood-2010-03-274811.

33. Мартинков В.Н., Новик Д.К., Веялкин И.В., Силин А.Е., Искров И.А. Заболеваемость Ph-негативными хроническими миелопролиферативными заболеваниями в Республике Беларусь. Гематология и трансфузиология. 2023; 68(3): 363 - 372. https://doi.org/10.35754/0234-5730-2023-68-3-363-372.

34. Shuvaev V., Martynkevich I., Abdulkadyrova A., et al. Ph-Negative Chronic Myeloproliferative Neoplasms - Population Analysis, a Single Center 10-years' Experience. Blood. 2014; 124(21): 5556. DOI: 10.1182/blood.V124.21.5556.5556.

35. Pizzi M, Croci GA, Ruggeri M, Tabano S, Dei Tos AP, Sabattini E, Gianelli U. The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases. Cancers (Basel). 2021 Nov 12; 13(22): 5666. doi: 10.3390/cancers13225666.

36. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 Jan 8; 350(2): 114-24. doi: 10.1056/NEJMoa035572. PMID: 14711910.

37. Gerds AT, Gotlib J, Ali H, et.al. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Sep; 20(9): 1033 - 1062. doi: 10.6004/jnccn.2022.0046.

38. Subortseva I, Melikyan A, Kovrigina A, et al. Clinical features of latent/masked polycythemia vera (single center experience). Haematologica. 2016; 101: 812.

39. Суборцева И.Н., Меликян А.Л., Ковригина А.М. и др. Латентная истинная полицитемия. Гематология и трансфузиология. 2016; 61(1): 72. [Subortseva IN, Melikyan AL, Kovrigina AM, et al. Latent polycythemia vera. Gematologiya i transfuziologiya. 2016; 61(1): 72. (In Russ)].

40. Brodmann S, Passweg JR, Gratwohl A, Tichelli A, Skoda RC. Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol. 2000 Jun; 79(6): 312-8. doi: 10.1007/s002779900136.

41. Marchioli R, Finazzi G, Specchia G, et.al. CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 Jan 3; 368(1): 22 - 33. doi: 10.1056/NEJMoa1208500.

42. Song IC, Kang S, Lee MW, Ryu H, Lee HJ, Yun HJ, Jo DY. Acquired von willebrand syndrome in patients with philadelphia-negative myeloproliferative neoplasm. Blood Res. 2023 Mar 31; 58(1): 42 - 50. doi: 10.5045/br.2023.2022218.

43. Tefferi A, Rumi E, Finazzi G, et.al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013 Sep; 27(9): 1874-81. doi: 10.1038/leu.2013.163.

44. Tefferi A, Guglielmelli P, Lasho TL, et.al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020 Apr; 189(2): 291 - 302. doi: 10.1111/bjh.16380.

45. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010; 148(6): 961-3. doi: 10.1111/j.1365-2141.2009.08019.x.

46. Crisa E, Venturino E, Passera R, et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010; 89(7): 691-9. doi: 10.1007/s00277-009-0899-z.

47. Ковалева Л.Г., Меликян А.Л., Ко П.И., Седова Г.Т., Петров М.М. Эритроцитаферез в комплексном лечении истинной полицитемии. Гематология и трансфузиология. 1987; 32(11): 10 - 14.

48. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev. 2003; 2(1): 15 - 28. doi: 10.1038/nrd985.

49. Manoharan A, Gemmell R, Cavanaugh L, Shadood N. Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis. Clin Appl Thromb Hemost. 2022 Jan - Dec; 28: 10760296221117482. doi: 10.1177/10760296221117482.

50. Gill H, Leung GMK, Yim R, Lee P, Pang HH, Ip HW, Leung RYY, Li J, Panagiotou G, Ma ESK, Kwong YL. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting. Hematology. 2020 Dec; 25(1): 247 - 257. doi: 10.1080/16078454.2020.1780755.

51. Wang R, Shallis RM, Stempel JM, et.al. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Adv. 2023 Mar 14; 7(5): 734 - 743. doi: 10.1182/bloodadvances.2022008259.

52. Суборцева И.Н., Гилязитдинова Е.А., Колошейнова Т.И. и др. Предварительные результаты исследования по оценке эффективности и безопасности лечения пациентов с истинной полицитемией и эссенциальной тромбоцитемией цепэгинтерфероном a-2b. Клиническая онкогематология. 2017; 10(4): 582.

53. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer. 2006 Aug 1; 107(3): 451-8. doi: 10.1002/cncr.22026. PMID: 16804923.

54. Huang B.-T., Zeng Q.-C., Zhao W.-H., Li B.-S., Chen R.-L. Interferon - 2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leuk. Res. 2014; 38: 1177 - 1183. doi: 10.1016/j.leukres.2014.06.019.

55. Kiladjian J.-J., Mesa R.A., Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011; 117: 4706 - 4715. doi: 10.1182/blood-2010-08-258772.

56. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008; 22(11): 1990-8. doi: 10.1038/leu.2008.280.

57. Меликян А.Л., Суборцева И.Н. Материалы 57-го конгресса Американского гематологического общества (декабрь 2015 г., Орландо). Клиническая онкогематология. 2016; 9(2): 218-28.

58. Sun Y, Cai Y, Cen J, Zhu M, Pan J, Wang Q, Wu D, Chen S. Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World. Front Oncol. 2021 Dec 21; 11: 797825. doi: 10.3389/fonc.2021.797825.

59. Muller EW, de Wolf JT, Egger R, et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. Brit J Haematol. 1995; 89: 313 - 318.

60. Samuelsson J, Hasselbalch H, Bruserud O, et.al. Nordic Study Group for Myeloproliferative Disorders. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006 Jun 1; 106(11): 2397-405. doi: 10.1002/cncr.21900.

61. Falchi L, Newberry KJ, Verstovsek S. New Therapeutic Approaches in Polycythemia Vera. Clin Lymphoma Myel Leuk. 2015; 15: 27 - 33. doi: 10.1016/j.clml.2015.02.013.

62. Alvarez-Larr n A, Abraldes JG, Cervantes F, Hern ndez-Guerra M, Vizzutti F, Miquel R, Gilabert R, Giusti M, Garcia-Pagan JC, Bosch J. Portal hypertension secondary to myelofibrosis: a study of three cases. Am J Gastroenterol. 2005 Oct; 100(10): 2355-8. doi: 10.1111/j.1572-0241.2005.50374.x. PMID: 16181389.

63. lvarez-Larran A, Martinez-Aviles L, Hernandez-Boluda JC, Ferrer-Marin F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martinez-Trillos A, Gomez-Casares MT, Dur n MA, Marcote B, Ancochea A, Senin A, Angona A, Gomez M, Vicente V, Cervantes F, Bellosillo B, Besses C. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol. 2014 Dec; 93(12): 2037-43. doi: 10.1007/s00277-014-2152-7.

64. Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018 Oct; 32(10): 2105 - 2116. doi: 10.1038/s41375-018-0207-9.

65. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013; 121(23): 4778-81. doi: 10.1182/blood-2013-01-478891.

66. Кузнецова П.И., Танашян М.М., Меликян А.Л. и др. Цереброваску-лярная патология при миелопролиферативных заболеваниях. Неврология и нейрохирургия. Восточная Европа. 2015; 5(0): 44-6.

67. Танашян М.М., Кузнецова П.И., Лагода О.В. и др. Миелопролифе-ративные заболевания и ишемический инсульт. Анналы клинической и экспериментальной неврологии. 2014; 8(2): 41-5.

68. Mancuso S, Accurso V, Santoro M, Raso S, Contrino AD, Perez A, Di Piazza F, Florena AM, Russo A, Siragusa S. The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors. Adv Hematol. 2020 Mar 27; 2020: 9124821. doi: 10.1155/2020/9124821.

69. Tefferi, A., Alkhateeb, H. & Gangat, N. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. Blood Cancer J. 13, 108 (2023). https://doi.org/10.1038/s41408-023-00878-8.

70. Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, Tefferi A. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016 Jun; 91(4): 390-4. doi: 10.1002/ajh.24293.

71. Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 Jan 25. doi: 10.1002/ajh.27216.

72. Hasselbalch HC, Silver RT. New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms. Hemasphere. 2021 Nov 18; 5(12): e645. doi: 10.1097/HS9.0000000000000645.

73. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010; 116(8): 1205-10. doi: 10.1182/blood-2010-01-263319.

74. Michiels JJ, Abels J, Steketee J, et al. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Int Med. 1985; 102(4): 466-71.

75. Суборцева И.Н., Меликян А.Л., Гилязитдинова Е.А., Колошейнова Т.И., Пустовая Е.И., Егорова Е.К., Ковригина А.М., Судариков А.Б., Абдуллаев А.О. Кожная токсичность гидроксикарбамида. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2018. 11(3): 252 - 258. DOI: 10.21320/2500-2139-2018-11-3-252-258.

76. Jean-Jacques Kiladjian, Pierre Zachee, Masayuki Hino, Fabrizio Pane, Tamas Masszi, Claire N Harrison, et al. Long-term Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Polycythaemia Vera (RESPONSE): 5-year Follow Up of a Phase 3 Study. Lancet Haematol. 2020; 7(3): e226 - e237. doi: 10.1016/S2352-3026(19)30207-8. Epub 2020 Jan 23.

77. Silver RT, Vandris K, Goldman JJ. Recombinant interferon - may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011 Jun 16; 117(24): 6669-72. doi: 10.1182/blood-2010-11-320069. Epub 2011 Apr 25. PMID: 21518929.

78. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer. 1998 Sep 15; 83(6): 1205-13. doi: 10.1002/(sici)1097-0142(19980915)83:6<1205::aid-cncr21>3.0.co;2-8. PMID: 9740087.

79. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles FJ. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1): 81-6. doi: 10.1007/s00280-002-0533-4.

80. Luo D, Luo J, Liang H, He Z, Chen H, Wen Z, Wang Q, Zhou X, Liu X, Xu N. [Efficacy and safety of peginterferon - 2b for treatment of myeloproliterative neoplasms]. Nan Fang Yi Ke Da Xue Xue Bao. 2023 Jun 20; 43(6): 1029 - 1034. Chinese. doi: 10.12122/j.issn.1673-4254.2023.06.20.

81. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001; 97(4): 863-6. doi: 10.1182/blood.v97.4.863.

82. Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017 Aug; 59: 110 - 116. doi: 10.1016/j.leukres.2017.06.001.

83. Passamonti F, Giorgino T, et al., A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis, Leukemia 31, 2726 - 2731 (2017). doi: 10.1038/leu.2017.169.

84. Tefferi A, Alkhateeb H, Gangat N. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. Blood Cancer J. 2023 Jul 18; 13(1): 108. doi: 10.1038/s41408-023-00878-8. PMID: 37460550; PMCID: PMC10352315.

85. Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS, Savi F, Moro A, Grifoni F, De Philippis C, Radice T, Bosari S, Lambertenghi Deliliers G, Cortelezzi A. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol. 2012 Sep; 25(9): 1193-202. doi: 10.1038/modpathol.2012.87.

86. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009; 113(13): 2895-901. doi: 10.1182/blood-2008-07-170449.

87. Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010; 116(15): 2857-8. doi: 10.1182/blood-2010-06-293415.

88. Gangat N, Caramazza D, Vaidya R, et al. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. J Clin Oncol. 2011; 29(4): 392-7. doi: 10.1200/JC0.2010.32.2446.

89. P. Guglielmelli et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology 2018 36310-318. DOI: 10.1200/JCO.2017.76.4886.

90. Loscocco GG, Rotunno G, Mannelli F, Coltro G, Gesullo F, Pancani F, Signori L, Maccari C, Esposito M, Paoli C, Vannucchi AM, Guglielmelli P. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis. Am J Hematol. 2024 Jan; 99(1): 68 - 78. doi: 10.1002/ajh.27136.

91. De Melo Campos P. Primary myelofibrosis: current therapeutic options. Rev Bras Hematol Hemoter. 2016; 38(3): 257-63. doi: 10.1016/j.bjhh.2016.04.003.

92. Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015; 29(11): 2126-33. doi: 10.1038/leu.2015.233.

93. How J, Hobbs G. Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature. Cancers (Basel). 2020 Jul 18; 12(7): 1954. doi: 10.3390/cancers12071954. PMID: 32708474; PMCID: PMC7409021.

94. Cervantes F, Alvarez-Larran A, Hernandez-Boluda J-C, et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol. 2004; 127(4): 399 - 403. doi: 10.1111/j.1365-2141.2004.05229.x.

95. Kroger N, Wolschke C, Gagelmann N. How I treat transplant-eligible patients with myelofibrosis. Blood. 2023 Nov 16; 142(20): 1683 - 1696. doi: 10.1182/blood.2023021218.

96. Gowin K, Ballen K, Ahn K, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020; 4(9): 1965 - 1973. doi: 10.1182/bloodadvances.2019001084.

97. Verstovsek S, Mesa RA, Livingston RA, Hu W, Mascarenhas J. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. J Hematol Oncol. 2023 Jul 27; 16(1): 82. doi: 10.1186/s13045-023-01471-z. PMID: 37501130.

98. Pemmaraju N, Bose P, Rampal R, Gerds AT, Fleischman A, Verstovsek S. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma. 2023 Jun; 64(6): 1063 - 1081. doi: 10.1080/10428194.2023.2196593.

99. Виноградова О.Ю. Шуваев В.А., Мартынкевич И.С. и др. Таргетная терапия миелофиброза. Клиническая онкогематология. 2017; 10(4): 471-8. doi: 10.21320/2500-2139-2017-10-4-471-478.

100. Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016; 91(12): 1262-71. doi: 10.1002/ajh.24592.

101. Baek DW, Cho HJ, Lee JM, Kim J, Moon JH, Sohn SK. Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis. Expert Rev Hematol. 2022 Jul; 15(7): 573 - 581. doi: 10.1080/17474086.2022.2088499.

102. Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, Polverelli N, Rumi E, Caramella M, Carraro MC, D'Adda M, Molteni A, Sissa C, Lunghi F, Vismara A, Ubezio M, Guidetti A, Caberlon S, Anghilieri M, Komrokji R, Cattaneo D, Della Porta MG, Giorgino T, Bert L, Brociner M, Kuykendall A, Passamonti F. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv. 2022 Mar 22; 6(6): 1855 - 1864. doi: 10.1182/bloodadvances.2021006889.

103. Меликян А.Л., Колосова Л.Ю., Соколова М.А. и др. Роль спленэктомии при лечении больных миелофиброзом. Терапевтический архив. 2013; 85(8): 69 - 76.

104. Melikyan AL, Kovrigina АМ, Sokolova MA, et al. The Role Of Splenectomy In The Treatment Of Myelofibrosis. Blood. 2013; 122(21): 4083. doi: 10.1182/blood. v122.21.4083.4083.

105. Doki N, Irisawa H, Takada S, et al. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis. Intern Med. 2007; 46(4): 187-90. doi: 10.2169/internalmedicine.46.1768.

106. Federico M, Pagnucco G, Russo A, Cardinale G, Guerrieri P, Scium F, Symonds C, Cito L, Siragusa S, Gebbia N, Lagalla R, Midiri M, Giordano A, Montemaggi P. Palliative splenic irradiation in primary and post PV/ET myelofibrosis: outcomes and toxicity of three radiation schedules. Hematol Rev. 2009 May 4; 1(1): e7. doi: 10.4081/hr.2009.e7.

107. Tefferi A, Jim nez T, Gray LA, Mesa RA, Chen MG. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. Eur J Haematol. 2001 Jan; 66(1): 37 - 42. doi: 10.1034/j.1600-0609.2001.00342.x.

108. Воробьев А.И. Руководство по гематологии. М.: Ньюдиамед, 2003. С. 9 - 15.

109. Mughal TI, Vaddi K, Sarlis NJ, et al. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014; 7: 89 - 101. doi: 10.2147/IJGM.S51800.

110. Neben-Wittich MA, Brown PD, Tefferi A. Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. Am J Hematol. 2010; 85(10): 808-10. doi: 10.1002/ajh.21819.

111. Elli EM, Belotti A, Aroldi A, Parma M, Pioltelli P, Pogliani EM. Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis. Mediterr J Hematol Infect Dis. 2014 Jun 1; 6(1): e2014042. doi: 10.4084/MJHID.2014.042.

112. Mascarenhasa J, Heaneyb ML, Najfelda V. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res. 2012; 36(12): 1500-4. doi: 10.1016/j.leukres.2012.08.013.

113. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofi-brosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013; 122(8): 1395-8. doi: 10.1182/blood-2013-03-488098.

114. Rinaldi I, Muthalib A, Wijayadi T, Sutedja B, Susanto N, Magdalena L, Tandaju JR, Wardhana IL, Winston K. Surgical Complications in Myeloproliferative Neoplasm Patient with Essential Thrombocythemia: A Case Report. Int Med Case Rep J. 2022 Sep 12; 15: 491 - 497. doi: 10.2147/IMCRJ.S375777.

115. Tiu A, Chiasakul T, Kessler CM. The Pitfalls of Global Hemostasis Assays in Myeloproliferative Neoplasms and Future Challenges. Semin Thromb Hemost. 2024 Mar; 50(2): 213 - 223. doi: 10.1055/s-0043-57010.

116. Schafer AI. Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2021 Apr; 35(2): 305 - 324. doi: 10.1016/j.hoc.2020.11.006.

117. Song IC, Kang S, Lee MW, Ryu H, Lee HJ, Yun HJ, Jo DY. Acquired von willebrand syndrome in patients with philadelphia-negative myeloproliferative neoplasm. Blood Res. 2023 Mar 31; 58(1): 42 - 50. doi: 10.5045/br.2023.2022218.

118. Tanashyan MM, Kuznetsova PI, Shabalina AA, Raskurazhev AA, Lagoda OV, Subortseva IN, Melikyan AL. Clinical Characteristics of Cerebrovascular Pathology with Patients Suffering from Ph-Negative Myeloproliferative Disease. Cerebrovasc Dis Extra. 2016; 6(3): 66 - 70. doi: 10.1159/000448597.

119. Wang D, Yu X, Sun Y, Lv Y, Li Y, Zhao P, Niu J, Zhang Y, Chen Y, Chen K, Chen Z, Liu W, Wang M, Hu X. Incidence of Thrombosis at Different Sites During the Follow-Up Period in Essential Thrombocythemia: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost. 2023 Jan - Dec; 29:10760296231181117. doi: 10.1177/10760296231181117.

120. Kuznetsova PI, Raskurazhev AA, Konovalov RN, Krotenkova MV, Chechetkin AO, Lagoda OV, Melikhyan AL, Tanashyan MM. Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders. J Clin Med. 2021 Dec 21; 11(1): 13. doi: 10.3390/jcm11010013.

121. Ferro JM, Infante J. Cerebrovascular manifestations in hematological diseases: an update. J Neurol. 2021 Sep; 268(9): 3480 - 3492. doi: 10.1007/s00415-021-10441-9.

122. Инсульт: пошаговая инструкция. Руководство для врачей. - 2-е изд., перераб. и доп Пирадов М.А., Максимова М.Ю., Танашян М.М. место издания ГЭОТАР-Медиа Москва, 288 с. 2020.

123. Simaan N, Molad J, Honig A, Filioglo A, Shbat F, Auriel E, Barnea R, Hallevi H, Seyman E, Mendel R, Leker RR, Peretz S. Characteristics of patients with cerebral sinus venous thrombosis and JAK2 V617F mutation. Acta Neurol Belg. 2023 Oct; 123(5): 1855 - 1859. doi: 10.1007/s13760-022-02077-x.

124. W.B. Chen, X.L. Wang Cerebral venous sinus thrombosis as the first manifestation of JAK2(V617F)-positive essential thrombocythemia Chin. Med. J., 131 (6) (2018), pp. 748 - 750.

125. Танашян М.М. Хроническая и острая цереброваскулярная патология при ph-негативных миелопролиферативных заболеваниях / Танашян М.М., Кузнецова П.И., Суборцева И.Н., Шабалина А.А., Лагода О.В., Меликян А.Л. // Гематология и трансфузиология. - 2016. - Том 61. N 3. - С. 46 - 50.

126. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Dec; 50(12): e344 - e418. doi: 10.1161/STR.0000000000000211.

127. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, Lennon O, Meschia JF, Nguyen TN, Pollak PM, Santangeli P, Sharrief AZ, Smith SC Jr, Turan TN, Williams LS. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul; 52(7): e364-e467. doi: 10.1161/STR.0000000000000375.

128. Шмаков Р.Г., Полушкина Е.С. Особенности репродуктивной функции у женщин с онкогематологическими заболеваниями. Современная онкология. 2008; 10(3): 68-9.

129. Шмаков, Роман Георгиевич. Репродуктивное здоровье женщин с онкогематологическими заболеваниями: автореферат дис. доктора медицинских наук: 14.00.01 / Шмаков Роман Георгиевич; [Место защиты: Науч. центр акушерства, гинекологии и перинатологии РАМН]. - Москва, 2008. - 46 с.

130. Качество жизни пациентов с миелопролиферативными новообразованиями и отношение пациентов и врачей к проблемам заболевания и лечения: результаты национальной наблюдательной программы МПН-КЖ-2020. Под ред. Т. И. Ионовой. М.: Практическая медицина, 2021. 36 с.

131. Ионова Т.И., Андреевская Е.А., Бабич Е.Н. и др. Актуальные аспекты качества жизни у пациентов с классическими Ph-негативными миелопролиферативными новообразованиями в Российской Федерации: обсуждение результатов национальной наблюдательной программы МПН-КЖ-2020. Клиническая онкогематология. 2021; 15(2): 176-97.

132. Ионова Т.И., Анчукова Л.В., Виноградова О.Ю. и др. Качество жизни и спектр симптомов у больных миелофиброзом на фоне терапии: данные клинической практики. Гематология и трансфузиология. 2016; 61 (1): 17 - 25. doi: 10.18821/0234-5730-2016-61-1-17-25.

133. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011; 118: 401 - 408.135.

134. Ионова Т.И., Виноградова О.Ю., Ефремова Е.В. и др. Разработка и результаты апробации русской версии опросника MPN10 для оценки симптомов у пациентов с миелопролиферативными новообразованиями с учетом международных рекомендаций. Клиническая онкогематология. 2020; 13(2): 176-84. doi: 10.21320/2500-2139-2020-13-2-176-184.

135. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012; 30: 4098 - 4103.

136. H.K. Rossau, M. Kjerholt, N. Brochmann, L.H. Tang, K.B. Dieperink. Daily living and rehabilitation needs in patients and caregivers affected by myeloproliferative neoplasms (MPN): A qualitative study. Journal of Clinical Nursing 2022 31 (7 - 8): 909 - 921 https://doi.org/10.1111/jocn.15944.

137. Шуваев В.А., Мартынкевич И.С. Как мы лечим истинную полицитемию. Онкогематология 2024; 19(1): 00 - 00. DOI: https://doi.org/10.17650/1818-8346-2024-19-1-00-00.

138. Миелопролиферативные новообразования / В.А. Шуваев, И.С. Мартынкевич, С.В. Сидоркевич. - 2-е изд., доп. и перераб. - М., 2023. - 336 с.

139. Silver RT, Barel AC, Lascu E, et al. The effect of initial molecular profile on response to recombinant interferon-alpha (rIFNalpha) treatment in early myelofibrosis. Cancer 2017; 123: 2680 - 2687. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28518222.

140. Sorensen AL, Mikkelsen SU, Knudsen TA, et al. Ruxolitinib and interferon-alpha2 combination therapy for patients with polycythemia vera or myelofibrosis: A phase II study. Haematologica 2020; 105: 2262 - 2272. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33054051.

141. Mesa, R.A. How I treat symptomatic splenomegaly in patients with myelofibrosis / R.A. Mesa // Blood. - 2009. - Vol. 113 N 22. - P. 5394 - 5400.

142. Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005 Feb; 74(2): 117-20.

143. Шмаков Р.Г., Полушкина Е.С., Ахмедова А.И., Соколова М.А., Виноградова М.А. Принципы ведения беременности у женщин с Ph-негативными миелопролиферативными новообразованиями. Акушерство и гинекология. 2017; 12: 46 - 51. https://dx.doi.org/10.18565/aig.2017.12.46-51.